Viewing Study NCT03533361

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:16 PM
Ignite Modification Date: 2026-01-28 @ 12:50 AM
Study NCT ID: NCT03533361
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2018-12-17
First Post: 2018-05-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
Sponsor: Eisai Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Thyroid Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None expanded access program View
None radioiodine refractory View
None differentiated View
None lenvatinib View